NHS

R&D

Early detection of cancers will require blood sweat and tear...

An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell.

News

Keytruda backed by NICE for late-stage oesophageal cancer

MSD's Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment.

Patients

Taking stock of NHS medicines optimisation

Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at loc

News

NHS England starts largest ever trial of Galleri cancer bloo...

A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects.<

News

NHS fast tracks access to Amgen's just-approved KRAS cancer ...

Amgen's first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement to allow early access while its cost-effectiveness is appraised

News

AZ CEO Soriot urges caution on COVID booster doses

The UK should think twice before backing widespread use of COVID-19 booster vaccinations, as to do so could place unnecessary burden on the NHS over the winter, according to AstraZeneca chi

Early detection of cancers will require blood sweat and tear...

Keytruda backed by NICE for late-stage oesophageal cancer

Taking stock of NHS medicines optimisation

NHS England starts largest ever trial of Galleri cancer bloo...

NHS fast tracks access to Amgen's just-approved KRAS cancer ...

AZ CEO Soriot urges caution on COVID booster doses

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

NHS

Editor's Picks